News >

Immunotherapy Arrives in Gastric Cancer

Angelica Welch
Published: Friday, Mar 30, 2018

Manish A. Shah, MD

Manish A. Shah, MD
In the past year, immunotherapy has emerged as one of the more promising approaches for the treatment of patients with gastric and gastroesophageal junction (GEJ) adenocarcinoma. Specifically, pembrolizumab (Keytruda) and nivolumab (Opdivo) have demonstrated strong clinical activity in this patient population.

State of the Science Summit™ on Gastrointestinal Cancers, Shah, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discussed the advancements being made in the treatment of patients with advanced gastric and GEJ cancer.

OncLive: Please provide an overview of your lecture.

Shah: I spoke about immunotherapy in stomach cancer and foregut [carcinoid] tumors like esophageal/GEJ cancers. This is obviously a new treatment for stomach and esophageal cancers, and it has demonstrated some activity in the advanced or third-line setting. Some of the key questions that I addressed were, “Who should be tested for immunotherapy? What is the best test? What is the best marker?”
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication